Prostate Cancer Management and Referral Guidance

Objectives

Provide primary care practitioners with consistent, culturally appropriate guidance to support men and their family and whānau to make informed, voluntary decisions about prostate cancer testing, investigation and treatment.[1][2]The overall aim is to improve equitable access to information, diagnostic services and treatment, promote consistent care across the pathway, and achieve more equitable outcomes.[1][3]

• Support informed discussion of the potential benefits and harms of prostate-specific antigen (PSA) testing and digital rectal examination (DRE), including false-positive and false-negative results, abnormal findings, subsequent investigation and treatment implications.[4][2]
• Balance earlier diagnosis of aggressive disease against the risks of detecting and treating cancers that may not progress during a man’s lifetime.[1]
• Prioritise discussion with men aged 50 to 70 years and men aged over 40 years with a family history of prostate cancer, while taking account of individual circumstances.[4]
• Offer annual PSA testing and DRE from age 40 to 70 years for men with at least one first-degree relative diagnosed with prostate cancer, while recognising that evidence for the optimal testing frequency is limited.[5][6]
• Reduce inequities by identifying and addressing barriers to information, diagnosis and treatment, particularly for Māori men and people living in rural or low-decile communities.[4][7]
• Explain the benefits and harms of biopsy, active surveillance and curative treatment, including possible adverse effects, disease progression and the need for ongoing monitoring.[2][8]
• Prioritise timely specialist assessment and treatment for men whose symptoms or test results suggest metastatic, advanced localised or otherwise high-suspicion prostate cancer.[6]

The guidance forms part of the wider Prostate Cancer Awareness and Quality Improvement Programme, intended to improve access, care consistency and outcomes for men in New Zealand.[1]

Implementation

Deliver the guidance through an algorithm and explanatory notes that enable primary care practitioners to hold tailored, informed-consent discussions, assess risk, arrange testing, repeat or interpret abnormal results, and refer men to specialist services according to clinical urgency.[1][3][9][6]Implementation is coordinated through the Ministry of Health and the Prostate Cancer Working Group, with local integration into clinical pathways by district health boards and primary health organisations.[1][3]

• Obtain verbal informed consent before PSA testing and/or DRE, ensuring that men understand possible benefits, harms, further procedures and treatment consequences.[7]
• Tailor communication to the man’s needs and health literacy, and offer the option of involving a partner, friend, family member or whānau member in consultations.[7]
• Address cultural barriers to DRE, including those that may affect Māori and Pasifika men, and explain that prostate cancer can occur despite a normal PSA result.[9]
• Assess practical barriers, including work, family and transport difficulties that may limit access to laboratories, outpatient appointments and further diagnostic assessment.[4][7]
• Perform PSA testing before DRE where possible, and avoid PSA testing within two days of DRE or three days of ejaculation or cycling.[8]
• Repeat a raised PSA test after 6 to 12 weeks to confirm the result, except where an abnormal DRE or red flag for advanced or metastatic disease requires earlier action.[8][9]
• Refer men with an abnormal DRE to urology, and refer men who decline DRE after appropriate information when they have two clearly abnormal PSA results.[9]
• Refer immediately to radiation oncology, or urology where radiation oncology is unavailable, when acute neurological symptoms indicate possible spinal cord or cauda equina compression.[5]
• Use urgency-based referral pathways, including immediate referral within 24 hours for severe back pain and acute neurological symptoms with PSA at least 10 micrograms per litre, urgent referral within 14 days for specified high-risk presentations, and routine referral within six to eight weeks for lower-risk combinations or two confirmed abnormal PSA results.[6]
• Use telephone consultation with the relevant on-call specialist where recommended, and contact radiation oncology first for immediate suspected spinal cord or cauda equina compression where that service is available.[6]
• Discuss active surveillance for localised low-risk disease, with repeat biopsies, PSA tests, DREs and occasional magnetic resonance imaging used for follow-up.[2]
• Explain curative treatment options, including radical prostatectomy, external beam radiation therapy, high-dose-rate brachytherapy and low-dose-rate brachytherapy, recognising their differing adverse-effect profiles.[8]
• Apply the Government’s Faster Cancer Treatment programme to reduce delays and standardise pathways, with men requiring immediate or urgent referral included in the 62-day health-target cohort.[10]

Relevant general practice, urology, nursing, pathology and prostate cancer organisations endorsed the guidance, while district health boards, primary health organisations, professional colleges and non-governmental organisations contribute to consultation and implementation.[1][3]The guidance is to be revised every two years as evidence evolves and updated versions published on the Ministry of Health website.[3]

Monitoring & Evaluation

Monitoring combines periodic evidence review, clinical follow-up requirements and referral timeliness, but the guidance does not establish a comprehensive programme-level measurement, reporting or accountability framework. The guidance is to be revised every two years as evidence on prostate cancer testing and treatment develops, with updated versions published on the Ministry of Health website.[3]The Prostate Cancer Awareness and Quality Improvement Programme provides the wider quality-improvement framework for improving access, consistency of care and outcomes for men in New Zealand.[1]

• Monitor men on active surveillance using repeat prostate biopsies, prostate-specific antigen (PSA) tests, digital rectal examinations (DREs) and, occasionally, magnetic resonance imaging.[2]
• Repeat a raised PSA test after 6–12 weeks to confirm the result, except where it is accompanied by an abnormal DRE or a red flag for advanced or metastatic disease.[8][9]
• Recognise that approximately 20–30 percent of men receiving active surveillance leave the programme for curative treatment or watchful waiting.[2]
• Apply annual PSA testing and DRE from ages 40 to 70 for men with at least one first-degree relative diagnosed with prostate cancer, while recognising that strong evidence on testing frequency is lacking.[5][6]
• Use age-specific PSA thresholds to support clinical decision-making: at least 4.0 micrograms per litre for men under 70 years, at least 10.0 micrograms per litre for men aged 71–75 years, and more than 20.0 micrograms per litre for men aged 76 years or older.[9]
• Interpret PSA results in the 4.0–10.0 micrograms per litre range as associated with a 40 percent chance of cancer detection on biopsy, and results in the 10.0–20.0 micrograms per litre range as associated with a 67 percent chance.[9]
• Use referral timeframes as operational performance expectations: immediate referral within 24 hours for specified suspected spinal cord or cauda equina compression cases, urgent referral within 14 days for specified high-risk presentations, and routine referral within six to eight weeks for lower-risk presentations or two clearly abnormal PSA results.[6]
• Apply the Faster Cancer Treatment 62-day health target to support timely appointments, investigations and treatment for men requiring immediate or urgent referral.[10]

Quantitative indicators for equity, testing quality, diagnostic access, treatment outcomes or service performance are not specified.[1][3]The supplied material does not set out routine reporting requirements, surveillance systems, audit processes, evaluation methods, named accountable bodies or formal accountability mechanisms beyond clinical referral criteria, the Faster Cancer Treatment target and periodic evidence review.[4][7][6][10]

Costing & Financing

No budget, costed implementation plan or financing framework is specified for the guidance.[1][3]The material does not identify funding sources, allocations, resource-mobilisation measures, funding gaps or economic assumptions.[4][7]

• Require local integration of guidance into prostate cancer clinical pathways through district health boards and primary health organisations, but do not specify the resources or funding required for this activity.[3]
• Address barriers to laboratory testing, outpatient appointments, diagnostic work and treatment access, including work, family and transport difficulties, but do not quantify associated costs or resource needs.[4][7]
• Use repeat testing, biopsy, imaging, specialist referral and active-surveillance follow-up where clinically indicated, but do not provide unit costs, service budgets or affordability assumptions.[2][8][9]
• Apply Faster Cancer Treatment referral pathways and the 62-day health target, but do not specify financing arrangements or additional capacity funding for timely delivery.[6][10]